Are Probiotics a Promising Treatment Strategy for Depression?
Are Probiotics a Promising Treatment Strategy for Depression?
Philadelphia, PA, November 14, 2013 /3BL Media/ – Probiotics are not new, but their status as a nutritional buzzword is. Most folks have now heard and seen the term countless times in commercials and advertisements, as yogurt, dietary supplement, natural food product, and even cosmetic companies promote their probiotic-containing products.
But what are they, and why are they important? Probiotics are live bacteria that help maintain a healthy digestive system. The development and marketing of products that contain live bacteria has flourished as there is a growing perceived interest in the ingestion of ‘natural foods’ that might promote health.
Many of the numerous health-improvement claims have yet to be supported scientifically, but these micro-organisms do exert positive effects in intestinal tracts, particularly when used to counteract the effects of antibiotics, which kill both ‘bad’ and ‘good’ bacteria. Indeed, the first known description of probiotics occurred in 1908 when a Russian scientist named Élie Metchnikoff observed that rural Europeans who regularly consumed fermented milk product had longer life spans.
Over the past few years, studies have been undertaken to explore the possible impact of probiotics on behavior. It is within this context that the concept of a psychobiotic has arisen.
The authors of a new review article in Biological Psychiatry, Timothy Dinan and his colleagues from University College Cork in Ireland, define a psychobiotic as “a live organism that, when ingested in adequate amounts, produces a health benefit in patients suffering from psychiatric illness.”
They review the evidence that these bacteria, when ingested in adequate amounts, offer enormous potential for the treatment of depression and other stress-related disorders.
The gut microbiota, which contains approximately 1 kg of bacteria, can be modulated by diet and many other factors. It is not static and can change from day to day, starting at birth. Evidence has shown that even the form of delivery (vaginal versus cesarean) alters an individual’s microbiota.
Early life stress, such as maternal separation, is known to induce long-term changes in the microbiome. Dinan and his colleagues review one study that assessed the potential benefits of a specific probiotic, B. infantis, in rats displaying depressive behavior due to maternal separation. The probiotic treatment normalized both their behavior and their previously-abnormal immune response. This preclinical study and others like it strongly support the hypothesis that probiotics have the potential to exert behavioral and immunological effects.
Some psychobiotics have been shown to have anti-inflammatory effects. This is important because depression and stress are both associated with inflammation in the body. Infectious diseases, such as syphilis and lyme disease, can also produce depressive states. Evidence suggests that immune activations, perhaps via psychobiotic action, could alleviate such states. According to the authors, “the intestinal microbial balance may alter the regulation of inflammatory responses and in so doing, may be involved in the modulation of mood and behavior.”
Human studies are still largely lacking, but a few have shown promising results. In one, healthy volunteers received either a probiotic combination (L. helveticus R0052 and B. longum) or placebo for 30 days. Those who received the probiotics reported lower stress levels. In a separate study, volunteers who consumed a yogurt containing probiotics reported improved mood.
“What is clear at this point is that, of the large number of putative probiotics, only a small percentage have an impact on behaviour and may qualify as psychobiotics,” said Dinan.
“This intriguing new area of research may open new possibilities for the treatment of depression,” said Dr. John Krystal, Editor of Biological Psychiatry.
For now, we must all wait for scientists to conduct large-scale, placebo-controlled trials to provide definitive evidence.
The article is “Psychobiotics: A Novel Class of Psychotropic” by Timothy G. Dinan, Catherine Stanton, and John F. Cryan (doi: 10.1016/j.biopsych.2013.05.001). The article appears in Biological Psychiatry, Volume 74, Issue 10 (November 15, 2013), published by Elsevier.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Dr. Timothy Dinan at +1 021 490 1224 or email@example.com.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 135 Psychiatry titles and 13th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2012 Impact Factor score for Biological Psychiatry is 9.247.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+1 214 648 0880